Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 11, 2019New England Journal of MedicineOpen Access

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

View Full Paper
Ask AI
Bookmark
Share

Authors

THTimothy P. HughesSouth Australia PathologyMMMichael J. MauroMemorial Sloan Kettering Cancer Center
Jorge E. Cortés
Jorge E. CortésAugusta University Health

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hughes et al. (2019) studied this question.

synapsesocial.com/papers/69dbcd29498b35d3e6a3d2a0https://doi.org/10.1056/nejmoa1902328
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors2007 · 299 citations
  2. 2Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia2009 · 244 citations
  3. 3Cancer phase I clinical trials: efficient dose escalation with overdose control1998 · 625 citations
  4. 4BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase2015 · 72 citations
  5. 5Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL12018 · 469 citations